Cargando…

Heat Shock Proteins in Lymphoma Immunotherapy

Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients. Lymphoma is a heterogeneous group of cancer, where the central roles in pathogenesis play immune evasion and dysregulation of multiple signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Albakova, Zarema, Mangasarova, Yana, Sapozhnikov, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012763/
https://www.ncbi.nlm.nih.gov/pubmed/33815422
http://dx.doi.org/10.3389/fimmu.2021.660085
_version_ 1783673434782302208
author Albakova, Zarema
Mangasarova, Yana
Sapozhnikov, Alexander
author_facet Albakova, Zarema
Mangasarova, Yana
Sapozhnikov, Alexander
author_sort Albakova, Zarema
collection PubMed
description Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients. Lymphoma is a heterogeneous group of cancer, where the central roles in pathogenesis play immune evasion and dysregulation of multiple signaling pathways. Immunotherapy-based approaches such as engineered T cells (CAR T), immune checkpoint modulators and NK cell-based therapies are now in the frontline of lymphoma research. Even though emerging immunotherapies showed promising results in treating lymphoma patients, low efficacy and on-target/off-tumor toxicity are of a major concern. To address that issue it is suggested to look into the emerging role of heat shock proteins. Heat shock proteins (HSPs) showed to be highly expressed in lymphoma cells. HSPs are known for their abilities to modulate immune responses and inhibit apoptosis, which made their successful entry into cancer clinical trials. Here, we explore the role of HSPs in Hodgkin and Non-Hodgkin lymphoma and their involvement in CAR T therapy, checkpoint blockade and NK cell- based therapies. Understanding the role of HSPs in lymphoma pathogenesis and the ways how HSPs may enhance anti-tumor responses, may help in the development of more effective, specific and safe immunotherapy.
format Online
Article
Text
id pubmed-8012763
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80127632021-04-02 Heat Shock Proteins in Lymphoma Immunotherapy Albakova, Zarema Mangasarova, Yana Sapozhnikov, Alexander Front Immunol Immunology Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients. Lymphoma is a heterogeneous group of cancer, where the central roles in pathogenesis play immune evasion and dysregulation of multiple signaling pathways. Immunotherapy-based approaches such as engineered T cells (CAR T), immune checkpoint modulators and NK cell-based therapies are now in the frontline of lymphoma research. Even though emerging immunotherapies showed promising results in treating lymphoma patients, low efficacy and on-target/off-tumor toxicity are of a major concern. To address that issue it is suggested to look into the emerging role of heat shock proteins. Heat shock proteins (HSPs) showed to be highly expressed in lymphoma cells. HSPs are known for their abilities to modulate immune responses and inhibit apoptosis, which made their successful entry into cancer clinical trials. Here, we explore the role of HSPs in Hodgkin and Non-Hodgkin lymphoma and their involvement in CAR T therapy, checkpoint blockade and NK cell- based therapies. Understanding the role of HSPs in lymphoma pathogenesis and the ways how HSPs may enhance anti-tumor responses, may help in the development of more effective, specific and safe immunotherapy. Frontiers Media S.A. 2021-03-18 /pmc/articles/PMC8012763/ /pubmed/33815422 http://dx.doi.org/10.3389/fimmu.2021.660085 Text en Copyright © 2021 Albakova, Mangasarova and Sapozhnikov http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Albakova, Zarema
Mangasarova, Yana
Sapozhnikov, Alexander
Heat Shock Proteins in Lymphoma Immunotherapy
title Heat Shock Proteins in Lymphoma Immunotherapy
title_full Heat Shock Proteins in Lymphoma Immunotherapy
title_fullStr Heat Shock Proteins in Lymphoma Immunotherapy
title_full_unstemmed Heat Shock Proteins in Lymphoma Immunotherapy
title_short Heat Shock Proteins in Lymphoma Immunotherapy
title_sort heat shock proteins in lymphoma immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012763/
https://www.ncbi.nlm.nih.gov/pubmed/33815422
http://dx.doi.org/10.3389/fimmu.2021.660085
work_keys_str_mv AT albakovazarema heatshockproteinsinlymphomaimmunotherapy
AT mangasarovayana heatshockproteinsinlymphomaimmunotherapy
AT sapozhnikovalexander heatshockproteinsinlymphomaimmunotherapy